Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials

Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials

Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic-Dysfunction Associated Steatohepatitis (MASH) are linked to obesity, type 2 diabetes, and metabolic syndrome, increasing liver-related morbidity and cardiovascular risk. Recent therapies, including Resmetiro...

Full description

Saved in:
Bibliographic Details
Main Authors: Hazem Ayesh, Azizullah Beran, Sajida Suhail, Suhail Ayesh, Kevin Niswender
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Biomedicines
Subjects:
Resmetirom
MASLD
MASH
FGF21
GLP-1
Online Access:https://www.mdpi.com/2227-9059/12/10/2328
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items